F

Fennec Pharmaceuticals Inc
NASDAQ:FENC

Watchlist Manager
Fennec Pharmaceuticals Inc
NASDAQ:FENC
Watchlist
Price: 7.49 USD 0.67% Market Closed
Market Cap: 255.8m USD

During the last 3 months Fennec Pharmaceuticals Inc insiders have not bought any shares, and sold 75.4k USD worth of shares. The stock price has dropped by 14% over this period (open performance analysis).

The last transaction was made on Dec 5, 2025 by Raykov Rosty , who sold 75.4k USD worth of FENC shares.

Last Transactions:
Raykov Rosty
$-75.4k
Raykov Rosty
$-80.9k
Rallis Chris A
$-9.7k
Raykov Rosty
$-86.1k
Raykov Rosty
$-77.8k
Hackman Jeffrey S.
$+97.6k
Raykov Rosty
$-113k
Hackman Jeffrey S.
$+7k
Raykov Rosty
$-63.1k
Rallis Chris A
$-7k
Raykov Rosty
$-52.5k
Raykov Rosty
$-67.9k
Rallis Chris A
$-8.1k
Raykov Rosty
$-66.6k
Raykov Rosty
$-14.8k
Raykov Rosty
$-4.8k
Raykov Rosty
$-10k
Rallis Chris A
$-39.4k
Raykov Rosty
$-10.5k
Rallis Chris A
$-6.4k
Raykov Rosty
$-12k
Raykov Rosty
$-13.4k
Raykov Rosty
$-15.2k
Rallis Chris A
$-7.1k
Raykov Rosty
$-14.9k
Raykov Rosty
$-16.4k
Raykov Rosty
$-22.2k
Haigh Adrian
$-207k
Haigh Adrian
$-207.4k
Haigh Adrian
$-51.3k
Haigh Adrian
$-51.3k
Haigh Adrian
$-51.3k
View All Transactions

During the last 3 months Fennec Pharmaceuticals Inc insiders have not bought any shares, and sold 75.4k USD worth of shares. The stock price has dropped by 14% over this period (open performance analysis).

The last transaction was made on Dec 5, 2025 by Raykov Rosty , who sold 75.4k USD worth of FENC shares.

Sold
0-3
months
75.4k USD
1
3-6
months
176.7k USD
2
6-9
months
313.4k USD
2
9-12
months
157.4k USD
2
Bought
0-3
months
0
0 USD
3-6
months
0
0 USD
6-9
months
1
104.6k USD
9-12
months
0
0 USD

Fennec Pharmaceuticals Inc
Insider Trading Chart

Fennec Pharmaceuticals Inc
Insiders Performance

1 Week Later 1 Month Later 3 Months Later 6 Months Later 1 Year Later
Average Return
Median Return
Win Rate

Fennec Pharmaceuticals Inc
Last Insider Transactions

Global
Insiders Monitor

Fennec Pharmaceuticals Inc
Glance View

Market Cap
255.8m USD
Industry
Biotechnology

Fennec Pharmaceuticals, Inc. operates as a biopharmaceutical company. The company is headquartered in Durham, North Carolina and currently employs 10 full-time employees. The company went IPO on 2001-06-05. The firm is focused on the development of PEDMARK for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The Company’s only product candidate in the clinical-stage of development is PEDMARK. The company announced two results of Phase III clinical trials for the prevention of cisplatin induced hearing loss, or ototoxicity in children, including the pivotal Phase III study SIOPEL 6 and the proof-of-concept Phase III study in collaboration with the Children’s Oncology Group (COG ACCL0431). PEDMARK has the potential to reduce the incidence and/or grade of chemotherapy-induced hearing loss. The Company’s four subsidiaries includes Oxiquant, Inc. and Fennec Pharmaceuticals, Inc., both Delaware corporations, Cadherin Biomedical Inc., a Canadian company, and Fennec Pharmaceuticals (EU) Limited (Fennec Limited), an Ireland company. Apart from Fennec Pharmaceuticals, Inc., all subsidiaries are inactive.

FENC Intrinsic Value
15.05 USD
Undervaluation 50%
Intrinsic Value
Price
F

What is Insider Trading?

Insider trading refers to the buying or selling of a company’s stock by individuals with access to non-public, material information about the company.

While legal insider trading occurs when insiders follow disclosure rules, illegal insider trading involves trading based on confidential information and is prohibited by law.

Why is Insider Trading Important?

It isn't a coincidence that corporate executives seem to always buy at the right times. After all, they have access to every bit of company information you could ever want.

However, the fact that company executives have unique insights doesn't mean that individual investors are always left in the dark. Insider trading data is out there for all who want to use it.

Peter Lynch

Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.

Back to Top